Alan B. Sandler

9.8k total citations · 2 hit papers
109 papers, 7.5k citations indexed

About

Alan B. Sandler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alan B. Sandler has authored 109 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 73 papers in Pulmonary and Respiratory Medicine and 35 papers in Molecular Biology. Recurrent topics in Alan B. Sandler's work include Lung Cancer Treatments and Mutations (70 papers), Lung Cancer Research Studies (40 papers) and Lung Cancer Diagnosis and Treatment (24 papers). Alan B. Sandler is often cited by papers focused on Lung Cancer Treatments and Mutations (70 papers), Lung Cancer Research Studies (40 papers) and Lung Cancer Diagnosis and Treatment (24 papers). Alan B. Sandler collaborates with scholars based in United States, Canada and United Kingdom. Alan B. Sandler's co-authors include Joan H. Schiller, David H. Johnson, Julie R. Brahmer, Janessa Laskin, Roy S. Herbst, David H. Johnson, Herbert I. Hurwitz, David Miles, Regula Deurloo and Robert L. Coleman and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Alan B. Sandler

106 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

2020 780 citations Alan B. Sandler et al. profile →
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

2000 606 citations Alan B. Sandler, Joachim von Pawel et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alan B. Sandler United States	44	4.5k	3.7k	2.4k	1.0k	638	109	7.5k
Philip Bonomi United States	42	4.9k 1.1×	4.4k 1.2×	2.1k 0.9×	978 0.9×	343 0.5×	241	8.0k
Rogério Lilenbaum United States	33	5.6k 1.3×	5.5k 1.5×	2.1k 0.9×	1.2k 1.2×	322 0.5×	105	8.4k
Rajeshwari Sridhara United States	53	4.8k 1.1×	2.9k 0.8×	3.0k 1.2×	1.3k 1.3×	788 1.2×	137	9.3k
Petr Zatloukal Czechia	33	3.7k 0.8×	3.4k 0.9×	1.6k 0.6×	603 0.6×	466 0.7×	87	5.7k
Glenwood Goss Canada	36	3.6k 0.8×	3.5k 0.9×	1.7k 0.7×	865 0.8×	560 0.9×	129	6.3k
Wilfried Eberhardt Germany	39	4.2k 0.9×	5.3k 1.4×	1.7k 0.7×	892 0.9×	379 0.6×	239	7.6k
Vassilis Georgoulias Greece	48	4.9k 1.1×	2.7k 0.7×	2.8k 1.1×	2.4k 2.3×	785 1.2×	296	8.3k
Hiroshi Nokihara Japan	40	3.9k 0.9×	3.3k 0.9×	1.7k 0.7×	935 0.9×	484 0.8×	237	5.9k
Chris H. Takimoto United States	45	4.8k 1.1×	2.5k 0.7×	3.6k 1.5×	859 0.8×	1.0k 1.6×	193	8.9k
Jyoti D. Patel United States	38	3.9k 0.9×	3.4k 0.9×	1.4k 0.6×	832 0.8×	495 0.8×	230	6.1k

Countries citing papers authored by Alan B. Sandler

Since Specialization

Citations

This map shows the geographic impact of Alan B. Sandler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan B. Sandler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan B. Sandler more than expected).

Fields of papers citing papers by Alan B. Sandler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan B. Sandler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan B. Sandler. The network helps show where Alan B. Sandler may publish in the future.

Co-authorship network of co-authors of Alan B. Sandler

This figure shows the co-authorship network connecting the top 25 collaborators of Alan B. Sandler. A scholar is included among the top collaborators of Alan B. Sandler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan B. Sandler. Alan B. Sandler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Keam, Bhumsuk, J-P. Machiels, Sjoukje F. Oosting, et al.. (2025). 1323MO ASPEN-03: A randomized phase II study of evorpacept in combination with pembrolizumab in patients with recurrent, unresectable or metastatic (R/M) PD-L1 positive head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 36. S770–S771.

Hong, Ming, Beatriz Cirauqui, J-P. Machiels, et al.. (2025). 1324MO ASPEN-04: A randomized phase II study of evorpacept in combination with pembrolizumab and chemotherapy in patients with recurrent, unresectable or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 36. S771–S771.

Wakelee, Heather A., Suzanne E. Dahlberg, Julie R. Brahmer, et al.. (2012). Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer. 76(3). 410–415. 26 indexed citations

Scagliotti, Giorgio V., Silvia Novello, Joan H. Schiller, et al.. (2012). Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 13(5). 391–395. 112 indexed citations

Hoang, Tien, Suzanne E. Dahlberg, Alan B. Sandler, et al.. (2012). Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab. Journal of Thoracic Oncology. 7(9). 1361–1368. 49 indexed citations

Horn, Leora & Alan B. Sandler. (2009). Angiogenesis in the Treatment of Non-Small Cell Lung Cancer. Proceedings of the American Thoracic Society. 6(2). 206–217. 28 indexed citations

Dowlati, Afshin, Robert J. Gray, Alan B. Sandler, Joan H. Schiller, & David H. Johnson. (2008). Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study. Clinical Cancer Research. 14(5). 1407–1412. 208 indexed citations

O’Brien, Mary, Mark A. Socinski, Igor Bondarenko, et al.. (2008). Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(7). 728–734. 96 indexed citations

Ramalingam, Suresh S., Suzanne E. Dahlberg, Corey J. Langer, et al.. (2007). Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. Journal of Clinical Oncology. 26(1). 60–65. 251 indexed citations

10.

Wakelee, Heather A., Suzanne E. Dahlberg, Joan H. Schiller, et al.. (2007). P1-052: Menopausal status of women may affect survival in advanced NSCLC: Analysis of recent Eastern Cooperate Oncology Group (ECOG) studies using age of 60 years or older as a surrogate marker. Journal of Thoracic Oncology. 2(8). S570–S570. 5 indexed citations

11.

Keedy, Vicki L. & Alan B. Sandler. (2007). Inhibition of angiogenesis in the treatment of non‐small cell lung cancer. Cancer Science. 98(12). 1825–1830. 49 indexed citations

12.

Kris, Mark G., Giuseppe Giaccone, Angela M. Davies, et al.. (2006). Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma. Journal of Thoracic Oncology. 1(9). S32–S36. 20 indexed citations

13.

Kobayashi, Hiroyuki, S. Gail Eckhardt, Jennifer A. Lockridge, et al.. (2005). Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 56(4). 329–336. 28 indexed citations

14.

Laskin, Janessa & Alan B. Sandler. (2004). Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Therapy. Seminars in Respiratory and Critical Care Medicine. 25. 17–27. 9 indexed citations

15.

Sandler, Alan B.. (2003). Chemotherapy for small cell lung cancer. Seminars in Oncology. 30(1). 9–25. 92 indexed citations

16.

Hanna, Nasser H., Michael S. Gordon, Karen Fife, & Alan B. Sandler. (2002). Phase I Trial of Topotecan Plus Vinorelbine With/Without Filgrastim (G-CSF) in Patients With Refractory Malignancies. American Journal of Clinical Oncology. 25(4). 337–339. 1 indexed citations

17.

Ganjoo, Kristen N., Michael S. Gordon, Alan B. Sandler, et al.. (2002). A Phase I Study of Weekly Gemcitabine and Docetaxel in Patients with Advanced Cancer: A Hoosier Oncology Group Study. Oncology. 62(4). 299–304. 11 indexed citations

18.

Hanna, Nasser H., Alan B. Sandler, Patrick J. Loehrer, et al.. (2002). Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer:a Hoosier Oncology Group randomized study. Annals of Oncology. 13(1). 95–102. 51 indexed citations

19.

Williams, Mark D. & Alan B. Sandler. (2001). The Epidemiology of Lung Cancer. Cancer treatment and research. 105. 31–52. 91 indexed citations

20.

Socinski, Mark A., Alan B. Sandler, Langdon L. Miller, et al.. (2001). Irinotecan (CPT-11) in Triplet Combinations in Patients with Advanced Non–Small-Cell Lung Cancer: A Review and Report of a Phase I/II Trial. Clinical Lung Cancer. 2. S26–S33. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact